Stockscreener 앱 받기
472.93
0.85%
2.41
전일 마감가:
$470.52
열려 있는:
$473.9
하루 거래량:
17,171
Relative Volume:
0.01
시가총액:
$119.99B
수익:
$11.74B
순이익/손실:
$3.68B
주가수익비율:
33.33
EPS:
14.1888
순현금흐름:
$3.34B
1주 성능:
-0.43%
1개월 성능:
+5.53%
6개월 성능:
+26.31%
1년 성능:
-3.03%
1일 변동 폭
$472.93
$474.99
1주일 범위
$461.52
$478.72
52주 변동 폭
$362.50
$519.68
버텍스 파마슈티컬 Stock (VRTX) Company Profile
명칭
Vertex Pharmaceuticals Inc
전화
(617) 341-6393
주소
50 NORTHERN AVENUE, BOSTON, MA
VRTX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VRTX
Vertex Pharmaceuticals Inc
|
472.93 | 119.38B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
780.04 | 81.46B | 14.34B | 4.50B | 3.88B | 41.57 |
|
ARGX
Argen X Se Adr
|
841.00 | 52.65B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
344.99 | 46.50B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
349.73 | 38.95B | 4.98B | 69.60M | 525.67M | 0.5198 |
버텍스 파마슈티컬 Stock (VRTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-28 | 재개 | Barclays | Overweight |
| 2026-01-22 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2026-01-12 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2026-01-07 | 재개 | UBS | Buy |
| 2026-01-06 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2025-12-03 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2025-11-13 | 개시 | Scotiabank | Sector Outperform |
| 2025-09-25 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2025-09-03 | 개시 | Raymond James | Mkt Perform |
| 2025-08-06 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2025-05-07 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2025-05-06 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2025-04-22 | 재개 | Cantor Fitzgerald | Overweight |
| 2025-02-12 | 업그레이드 | Canaccord Genuity | Sell → Hold |
| 2025-02-11 | 업그레이드 | Canaccord Genuity | Sell → Hold |
| 2025-01-30 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2024-12-20 | 재확인 | H.C. Wainwright | Buy |
| 2024-12-19 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2024-12-09 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-11-14 | 개시 | Citigroup | Buy |
| 2024-10-16 | 개시 | Scotiabank | Sector Perform |
| 2024-10-10 | 재개 | Raymond James | Mkt Perform |
| 2024-08-05 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2024-06-27 | 개시 | Redburn Atlantic | Buy |
| 2024-04-11 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2024-02-15 | 개시 | Wolfe Research | Outperform |
| 2024-02-06 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2024-02-02 | 다운그레이드 | Bernstein | Outperform → Mkt Perform |
| 2024-01-31 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2024-01-31 | 다운그레이드 | Robert W. Baird | Neutral → Underperform |
| 2024-01-24 | 다운그레이드 | Canaccord Genuity | Hold → Sell |
| 2023-12-14 | 재확인 | RBC Capital Mkts | Sector Perform |
| 2023-05-30 | 개시 | William Blair | Outperform |
| 2023-05-04 | 재개 | Piper Sandler | Overweight |
| 2023-03-21 | 개시 | Bernstein | Outperform |
| 2023-01-18 | 개시 | Canaccord Genuity | Hold |
| 2023-01-17 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2022-12-19 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-07-13 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-06-01 | 업그레이드 | Maxim Group | Hold → Buy |
| 2022-05-23 | 개시 | SVB Leerink | Mkt Perform |
| 2022-05-06 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2022-05-03 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2022-02-03 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-01-27 | 재확인 | JP Morgan | Overweight |
| 2022-01-27 | 재확인 | Morgan Stanley | Underweight |
| 2022-01-27 | 재확인 | RBC Capital Mkts | Outperform |
| 2022-01-27 | 재확인 | Stifel | Hold |
| 2022-01-27 | 재확인 | Wolfe Research | Outperform |
| 2022-01-20 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2021-12-09 | 개시 | Wells Fargo | Overweight |
| 2021-11-19 | 개시 | BMO Capital Markets | Market Perform |
| 2021-11-19 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2021-09-09 | 다운그레이드 | Stifel | Buy → Hold |
| 2021-09-07 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2021-07-20 | 다운그레이드 | SVB Leerink | Mkt Perform → Underperform |
| 2021-07-19 | 재개 | Wolfe Research | Outperform |
| 2021-07-01 | 개시 | Raymond James | Mkt Perform |
| 2021-06-11 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2021-02-23 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2021-02-02 | 재확인 | H.C. Wainwright | Buy |
| 2020-12-30 | 개시 | Daiwa Securities | Outperform |
| 2020-11-30 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-11-20 | 개시 | Bernstein | Outperform |
| 2020-10-28 | 개시 | UBS | Buy |
| 2020-07-31 | 재확인 | H.C. Wainwright | Buy |
| 2020-07-08 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-04-30 | 재확인 | H.C. Wainwright | Buy |
| 2020-04-28 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-03-04 | 개시 | Barclays | Overweight |
| 2020-01-31 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2019-11-19 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2019-11-12 | 개시 | SunTrust | Buy |
| 2019-10-17 | 재개 | BofA/Merrill | Buy |
| 2019-09-03 | 업그레이드 | Goldman | Neutral → Buy |
| 2019-08-01 | 다운그레이드 | Needham | Buy → Hold |
| 2019-05-23 | 재개 | Citigroup | Buy |
| 2019-05-21 | 개시 | Credit Suisse | Outperform |
| 2019-04-12 | 개시 | Evercore ISI | In-line |
| 2019-03-26 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2019-03-19 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2019-02-06 | 다운그레이드 | Maxim Group | Buy → Hold |
모두보기
버텍스 파마슈티컬 주식(VRTX)의 최신 뉴스
Does WuXi Trispecific T-cell Engager Deal Reshape the Bull Case for Vertex Pharmaceuticals (VRTX)? - simplywall.st
Is Vertex Pharmaceuticals (VRTX) Pricing Reflect Long Term Cash Flow Potential After Recent Pullback - Yahoo Finance
Vertex Pharma wins EU backing to expand label for Kaftrio cystic fibrosis drug - MSN
The Truth About Vertex Pharma: Why Wall Street Suddenly Can’t Shut Up - AD HOC NEWS
Callan Family Office LLC Has $4.39 Million Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Machina Capital S.A.S. Acquires Shares of 11,167 Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Rep. David Taylor Sells Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Stock - MarketBeat
WUXI BIO, Vertex Pharmaceuticals Sign License & Research Service Agreement for T-cell Engager - AASTOCKS.com
Biopharma bites: Updated data for Ultragenyx's gene therapy, AI newco's $13.5M seed round, plus more from NMD, Vertex - FirstWord Pharma
Is Trending Stock Vertex Pharmaceuticals Incorporated (VRTX) a Buy Now? - Yahoo Finance
Here's How Much a $1000 Investment in Vertex Pharmaceuticals Made 10 Years Ago Would Be Worth Today - Yahoo Finance
WuXi licenses trispecific immune engager to Vertex - The Pharma Letter
Vertex (VRTX) Secures Exclusive Rights for Innovative Autoimmune Treatment - GuruFocus
Vertex Pharmaceuticals Incorporated $VRTX Shares Sold by WCM Investment Management LLC - MarketBeat
Mediolanum International Funds Ltd Purchases 3,050 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
WuXi Biologics Jumps On Pact With Vertex Pharma For T-Cell Engager In Autoimmune Disease - Nasdaq
Targeted Cancer Therapy Market to Reach US$ 175.48 Billion by 2035 Driven by Precision Oncology Adoption, ADC Innovation, and Regulatory Productivity Says Astute Analytica - GlobeNewswire Inc.
WuXi Biologics and Vertex Pharmaceuticals Partner to Develop T-Cell Engager Immunotherapies - geneonline.com
WuXi Biologics Inc. and Vertex Pharmaceuticals Incorporated Sign License and Research Service Agreement for T-Cell Engager - marketscreener.com
WuXi Biologics and Vertex Sign License and Research Service Agreement for T-cell Engager - marketscreener.com
Vertex Pharmaceuticals (VRTX) Stock Analysis: A Healthcare Giant with 9.45% Potential Upside - DirectorsTalk Interviews
Top Biotech Stocks To Watch TodayFebruary 2nd - MarketBeat
Vertex Pharmaceuticals Inc (NASDAQ:VRTX) Presents a Compelling Growth and Breakout Opportunity - Chartmill
Principal Financial Group Inc. Reduces Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Atle Fund Management AB Reduces Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Incorporated $VRTX Holdings Lifted by National Pension Service - MarketBeat
Vertex Pharmaceuticals Incorporated $VRTX Shares Sold by TD Waterhouse Canada Inc. - MarketBeat
Vertex Pain Setback Prompts Fund Exit And Recheck Of Valuation Gap - Yahoo Finance
Why Analysts Are Positive on Vertex Pharmaceuticals Incorporated (VRTX)'s Story - Finviz
Biotech Stocks To Keep An Eye OnJanuary 31st - MarketBeat
Why Analysts Are Positive on Vertex Pharmaceuticals Incorporated (VRTX)’s Story - Insider Monkey
Welch & Forbes LLC Buys 3,102 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
AustralianSuper Pty Ltd Trims Stake in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Why Vertex Pharmaceuticals (VRTX) Dipped More Than Broader Market Today - Yahoo Finance
10 Most Profitable Healthcare Stocks to Buy - Insider Monkey
Vertex Pharmaceuticals Incorporated $VRTX Shares Sold by Fidelis Capital Partners LLC - MarketBeat
Prediction: 2026 Will Be the Year of Vertex Pharmaceuticals - The Globe and Mail
Best Biotech Stocks To Watch NowJanuary 29th - MarketBeat
What's Driving the Market Sentiment Around Vertex Pharmaceuticals Inc? - Benzinga
Assessing Vertex Pharmaceuticals (VRTX) Valuation After Fund Exit And Setback For Journavx Pain Label - simplywall.st
Vertex Pharmaceuticals Incorporated $VRTX Shares Acquired by Strategic Advisors LLC - MarketBeat
Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) Presents a Compelling Value Case - Chartmill
New York State Common Retirement Fund Cuts Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Mirae Asset Global Investments Co. Ltd. Buys 6,468 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Truist Financial Corp Sells 66,225 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharma upgraded at RBC Capital Markets citing upside in 2026 - MSN
Barclays Upgrades Vertex Pharmaceuticals (VRTX) - Nasdaq
Promising Biotech Stocks To ResearchJanuary 28th - MarketBeat
Barclays Upgrades Vertex Pharmaceuticals (VRTX) with Increased P - GuruFocus
Bank of America Securities Keeps Their Buy Rating on Vertex Pharmaceuticals (VRTX) - The Globe and Mail
Little House Capital LLC Increases Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
버텍스 파마슈티컬 (VRTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.75%
1.10%
자본화:
|
볼륨(24시간):